08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Eisai sales and marketing update

Eisai launched 5 and 10 mg Aciphex Sprinkle delayed-release rabeprazole capsules in the U.S. to treat gastroesophageal reflux disease (GERD) for up to 12 weeks in children ages one to 11 years. FDA approved the...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Aciphex Sprinkle delayed-release rabeprazole regulatory update

FDA approved 5 and 10 mg Aciphex Sprinkle delayed-release rabeprazole capsules treat gastroesophageal reflux disease (GERD) for up to 12 weeks in children ages 1-11 years. A 20 mg tablet formulation of Aciphex is approved...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that...